Autolus Therapeutics (AUTL) Cash from Investing Activities (2017 - 2025)

Autolus Therapeutics' Cash from Investing Activities history spans 6 years, with the latest figure at $86.5 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 122.56% year-over-year to $86.5 million; the TTM value through Dec 2025 reached $158.5 million, up 140.16%, while the annual FY2025 figure was $158.5 million, 140.16% up from the prior year.
  • Cash from Investing Activities reached $86.5 million in Q4 2025 per AUTL's latest filing, up from $35.5 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $95.9 million in Q2 2025 to a low of -$383.6 million in Q4 2024.
  • Average Cash from Investing Activities over 4 years is -$19.1 million, with a median of -$1.5 million recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: plummeted 25870.82% in 2024, then soared 11504.88% in 2025.
  • A 4-year view of Cash from Investing Activities shows it stood at -$633000.0 in 2022, then crashed by 133.33% to -$1.5 million in 2023, then tumbled by 25870.82% to -$383.6 million in 2024, then soared by 122.56% to $86.5 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Cash from Investing Activities are $86.5 million (Q4 2025), $35.5 million (Q3 2025), and $95.9 million (Q2 2025).